Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiotricityBTCY -0.18%20 OCF Yield % is -31.45 as of Jul. 19, 2026. GuruFocus rates BTCY with a GF Score™ of 20/100 and a GF Value™ of $0.39 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Biotricity ranks worse than 88.59% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Biotricity OCF Yield % Related Terms
Biotricity OCF Yield % Historical Data
* Premium members only.
The historical data trend for Biotricity's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biotricity's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotricity OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Biotricity's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotricity (BTCY) has a OCF Yield % of -31.45 as of Jul. 19, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Biotricity and its competitors. According to the industry distribution chart, Biotricity ranks #753 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 88.6%.
Is Biotricity's OCF Yield % too high?
Biotricity's current OCF Yield % is -31.45. Based on the distribution chart, Biotricity ranks #753 out of 850 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Biotricity has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biotricity's OCF Yield % compare to FEED and LUDG?
According to the Medical Devices & Instruments industry distribution chart, Biotricity ranks #753 out of 850 companies for OCF Yield %. This places Biotricity in the lower half of its industry. The industry median OCF Yield % is 1.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.74, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Biotricity and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotricity's current OCF Yield % is -31.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotricity stock overvalued right now?
Based on GuruFocus' analysis, Biotricity (BTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $0.39, compared to a current price of $0.11 — trading 71.1% below its estimated fair value. The current OCF Yield % is -31.45. Biotricity's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Biotricity (BTCY), the current OCF Yield % is -31.45 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotricity (BTCY) Overvalued in 2026?
Based on GuruFocus' analysis, Biotricity stock appears to be undervalued.
The current stock price of $0.11 is trading 71.1% below its estimated GF Value™ of $0.39.
GuruFocus considers Biotricity to be Possible Value Trap.
Key valuation signals for BTCY:
OCF Yield %: -31.45
GF Value™: $0.39 vs. price of $0.11 (71.1% below fair value)
No single metric tells the full story. See the BTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed; Bioheart, which is a personal heart monitor; Biokit, and Biocare health.
20GF Score
Get the complete analysis for BTCY
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTCY has been successfully added to your 
